SEC Form 4 · accession 0001140361-18-017877
Sienna Biopharmaceuticals, Inc. · SNNA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd Harris
Officer — Head of Corporate Development · Director
Period of report
Apr 5, 2018
Accepted (ET)
Apr 9, 2018 · 7:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001656328
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Apr 5, 2018 | S | 5,386 | $20.001 | D | 596,680 | D | |
| Common Stock | Apr 9, 2018 | S | 2,824 | $20.00 | D | 593,856 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 22, 2017.
- F2This transaction was executed in multiple trades in prices ranging from $20.00 to $20.01, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.